Teva announces Copaxone patent win

|By:, SA News Editor

Teva (TEVA) scores a favorable court ruling in the Netherlands, as a District Court of the Hague rejects the grounds of invalidity Mylan (MYL) raised against a European Copaxone patent.

Generic versions of the RRMS drug "would require a marketing authorization from the Netherlands Medicines Evaluation Board," TEVA notes, adding that the complexity of the drug opens the door for "unpredictable differences between a proposed generic product and Copaxone [which could] lead to immunogenic effects in patients." (PR)

Subscribe for full text news in your inbox